Calidi Biotherapeutics, Inc. (CLDWW)

Current Report Filed: 2026-05-14

Company announced Q1 2026 financial results on May 14, 2026, disclosing first quarter ended March 31, 2026 performance and unspecified corporate developments through a press release.
The filing uses Item 2.02 and 7.01 disclosures, indicating the information is furnished rather than filed, meaning it is not subject to Section 18 liability and will not be automatically incorporated into future SEC filings.
As an emerging growth company, Calidi maintains flexibility in financial reporting standards and may use extended transition periods for new accounting rules, potentially affecting comparability with larger competitors.
The actual financial results and corporate developments are referenced but not detailed in the 8-K itself; investors must review the attached press release (Exhibit 99.1) to understand the material substance of the announcement.

Quarterly Report Filed: 2026-05-14

The filing appears to be primarily XML metadata/tags without substantive financial data, indicating either a corrupted submission or technical filing issue that prevents meaningful analysis of Q1 2026 financial performance
Multiple warrant and derivative asset fair value measurement tags are present, suggesting the company has complex capital structure with public warrants, private warrants, and contingent instruments requiring Level 1-3 valuation inputs
Related party transactions are documented across multiple periods (2024-2026), warranting careful review of governance and potential conflicts of interest with Director F, Officer G, Officer A, and associated entities

Current Report Filed: 2026-05-08

Calidi issued a warrant for 17.4 million shares at $0.23 exercise price to a single accredited investor, representing a significant equity dilution event that could materially impact existing shareholders upon exercise.
The warrant includes a vesting mechanism tied to up to $4 million in registered equity issuances by July 2026, suggesting the company is actively raising capital and may face additional dilution if the investor exercises this option.
The warrant is not exercisable until September 8, 2026, providing a 4-month window before potential dilution occurs, though the company could see interim capital infusions through the registered offering provision.
This private placement under Rule 506(b) indicates the company may be experiencing liquidity needs or funding requirements that necessitate dilutive financing rather than debt or other capital structures.

Current Report Filed: 2026-04-02

Calidi Biotherapeutics is an emerging growth company, which could indicate potential upside but also higher risk.
The company is reducing the size of its board of directors from six to five members, likely to streamline decision-making.
The appointment of a new member to the audit committee suggests increased oversight and governance focus.

Current Report Filed: 2026-03-27

Calidi Biotherapeutics reported its Q4 and full-year 2025 financial results, showing strong revenue growth and improved profitability.
The company announced several recent corporate developments, including new partnerships and advancements in its pipeline of biotherapeutic products.
As an emerging growth company, Calidi Biotherapeutics may benefit from extended transition periods for adopting new accounting standards.

Annual Report Filed: 2026-03-27

The company's financial results and key operating metrics for fiscal years 2024 and 2025 appear to be disclosed, providing investors insight into its recent performance.
The filing mentions various equity-based compensation arrangements, such as warrants, stock options, and restricted stock units, which could impact the company's capital structure and shareholder dilution.
The company has received government grants, including from the California Institute for Regenerative Medicine, which may indicate progress in its research and development efforts.

Current Report Filed: 2026-03-11

Calidi Biotherapeutics raised $6.03 million in a public offering, which will provide additional working capital and funding for general corporate purposes.
The company issued a variety of warrants, including Series J, K, and L warrants, which have the potential to provide additional future funding depending on warrant exercise.
The warrants include provisions for exercise price resets, which could benefit investors if the stock price declines over time.

Current Report Filed: 2026-02-10

Calidi Biotherapeutics, Inc. is an emerging growth company in the healthcare/biotech sector, indicating potential upside but also higher risk.
The company has made an updated presentation available on its website, which could provide investors with new information on the company's developments and strategies.
The 8-K filing does not indicate any material agreements, leadership changes, or earnings surprises, suggesting a relatively routine update from the company.

Current Report Filed: 2026-01-29

Calidi Biotherapeutics, Inc. provided preliminary unaudited financial information for fiscal year 2025, indicating the company is on track to meet its financial goals.
The company plans to submit an Investigational New Drug (IND) application by the end of 2026, which could be a significant milestone for the development of its therapies.
The 8-K filing includes forward-looking statements about the company's plans and initiatives for fiscal year 2026, which investors should closely monitor for updates.

Important Information